New injection shows promise for weight loss in early trial
NCT ID NCT06532578
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new drug called CPX101 in 240 overweight or obese adults without diabetes. Participants received different doses of CPX101 or a placebo by injection for 24 weeks. The goal was to see if the drug helps with weight loss and to check its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CPX101 (a biologic drug given by injection)
- What this could lead to
- If it works, this could lead to a new treatment option for weight loss in people who are overweight or obese.
- What could go wrong
- This is an early Phase 2 trial with only 240 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Paratus Clinical Research
Chatswood, New South Wales, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Can a Boron-Based pill tame obesity and blood sugar?
- Citrus flavonoid hesperidin put to the test as a brain booster for overweight adults
- Could dimming lights and early dinners boost insulin sensitivity?
- Extra sleep may boost insulin sensitivity and cut heart risk
- Can changing when and what you eat trick your body into making less fat?